Kronox Lab Sciences (KRONOX) Fundamentals 2026 — P/E 19.9x, Revenue Analysis | SniperIQ
Kronox Lab Sciences (KRONOX) is a India-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ₹552 Crore, trading at ₹148.84 on the NSE. This SniperIQ fundamentals page covers Kronox Lab Sciences's valuation (P/E 19.9x, P/B 4.8x), profitability (net margin 27.2%), revenue (₹101 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kronox Lab Sciences's market cap?
Kronox Lab Sciences (KRONOX) has a market capitalization of approximately ₹552 Crore, trading at ₹148.84 on the NSE. Market cap moves with the live share price.
What is Kronox Lab Sciences's P/E ratio?
Kronox Lab Sciences's trailing twelve-month P/E ratio is 19.9x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Kronox Lab Sciences?
Kronox Lab Sciences runs a net profit margin of 27.2%, a gross margin of 53.9%, and an operating margin of 31.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kronox Lab Sciences generate?
Kronox Lab Sciences reported revenue of ₹101 Crore for fiscal year 2025, with net income of ₹28 Crore and earnings per share (EPS) of 7.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kronox Lab Sciences pay a dividend?
Kronox Lab Sciences offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kronox Lab Sciences financially healthy?
Kronox Lab Sciences carries a debt-to-equity ratio of 0.01x and a current ratio of 7.60x, with a market beta of 0.98. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kronox Lab Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kronox Lab Sciences (KRONOX) the key facts are: market cap ₹552 Crore, P/E 19.9x, revenue ₹101 Crore, 52-week range 96-187.91. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Kronox Lab Sciences's full fundamentals live
Get Kronox Lab Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.